Snyder Richard 4
4 · MICRUS ENDOVASCULAR CORP · Filed Sep 28, 2010
Insider Transaction Report
Form 4
Snyder Richard
VP, Human Resources
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$5.89/sh−4,167$24,544→ 0 totalExercise: $17.51Exp: 2017-11-12→ Common Stock (4,167 underlying) - Disposition to Issuer
Common Stock
2010-09-27−4,802→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$14.21/sh−8,855$125,830→ 0 totalExercise: $9.19Exp: 2019-05-26→ Common Stock (8,855 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$11.98/sh−15,549$186,277→ 0 totalExercise: $11.42Exp: 2018-05-14→ Common Stock (15,549 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$9.67/sh−29,132$281,706→ 0 totalExercise: $13.73Exp: 2016-09-01→ Common Stock (29,132 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$11.98/sh−4,451$53,323→ 0 totalExercise: $11.42Exp: 2018-05-14→ Common Stock (4,451 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$14.21/sh−16,145$229,420→ 0 totalExercise: $9.19Exp: 2019-05-26→ Common Stock (16,145 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$5.89/sh−15,833$93,256→ 0 totalExercise: $17.51Exp: 2017-11-12→ Common Stock (15,833 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$9.67/sh−20,868$201,794→ 0 totalExercise: $13.73Exp: 2016-09-01→ Common Stock (20,868 underlying)
Footnotes (3)
- [F1]1,628 shares of common stock were purchased under Micrus Endovascular Corporation's 2005 Employee Stock Purchase Plan as follows: 1,022 shares on March 31, 2010 and 606 shares on September 23, 2010.
- [F2]Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., each share of common stock held by the reporting person was converted into the right to receive $23.40 in cash, without interest.
- [F3]Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., this stock option was converted into the right to receive an amount in cash per share subject to the stock option equal to the excess of the per share merger consideration of $23.40 over the per share exercise price of such stock option, without interest.